**Supplementary Table 13. Spearman relationship between serum HBsAg and clinical index for liver injury for HBeAg-positive patients with different HBV DNA levels in cohort A and independent validation Nanjing cohort**

|  |  |  |  |
| --- | --- | --- | --- |
| Spearman Rho (*P* value) between Serum HBsAg and | | DNA>2×106 IU/mL subgroup | DNA≤2×106 IU/mL subgroup |
| Cohort A |  | （n=286） | (n=43) |
|  | ALT | -0.325(0.000) | -0.248(0.109) |
|  | AST | -0.402(0.000) | -0.231(0.135) |
|  | GGT | -0.278(0.000) | -0.075(0.635) |
|  | Liver necroinflammatory grade\* | -0.403(0.000) | -0.011(0.942) |
| Independent validation Nanjing Cohort | | (n=2041) | (n=583) |
|  | ALT | -0.379 (<0.001) | -0.094 (0.042) |
|  | AST | -0.436 (<0.001) | -0.135 (0.003) |
|  | GGT | -0.369 (<0.001) | -0.229 (<0.001) |
|  | Liver necroinflammatory grade\* | -0.464 (<0.001) \* | -0.198 (0.090) # |

\*n=329; #n=128. HBsAg, hepatitis surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase.